Patents by Inventor Erol Ali Faruk

Erol Ali Faruk has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Process for the preparation of azabicyclic derivatives
    Patent number: 5808075
    Abstract: A process for the preparation of a compound of formula (I) or a pharmaceutically acceptable salt thereof wherein R.sub.1 represents (a) in which r represents an integer of 2 to 4, s represents 1 or 2 and t represents 0 or 1; R.sub.2 is a group OR.sub.4, where R.sub.4 is C.sub.1-4 alkyl, C.sub.2-4 alkenyl or C.sub.2-4 alkynyl or a group OCOR.sub.5 where R.sub.5 is hydrogen or R.sub.4 ; and R.sub.3 is CN; said process comprising reacting a compound of formula (II) wherein R.sub.1 ' is R.sub.1 or a group convertible thereto, and R.sub.3 ' is an electron withdrawing group, with a source of nitrous acid, and thereafter converting the resulting .dbd.NOH group to .dbd.NR.sub.2 wherein R.sub.2 is as defined in formula (I), converting R.sub.1 ' and R.sub.3 ' when other than R.sub.1 and R.sub.3 to R.sub.1 and R.sub.3, and thereafter optionally forming a pharmaceutically acceptable salt.
    Type: Grant
    Filed: November 12, 1996
    Date of Patent: September 15, 1998
    Inventors: Steven Mark Bromidge, Martyn Voyle, Erol Ali Faruk, Mark Jason Hughes, John Kitteringham, Gary Thomas Borrett
  • Process for the preparation of azabicycloc derivatives
    Patent number: 5773619
    Abstract: A process for the preparation of a compound of formula (I) or a pharmaceutically acceptable salt thereof: ##STR1## wherein R.sub.1 represents ##STR2## in which r represents an integer of 2 to 4, s represents 1 or 2 and t represents 0 or 1;R.sub.2 is a group OR.sub.4, where R.sub.4 is C.sub.1-4 alkyl, C.sub.2-4 alkenyl or C.sub.2-4 alkynyl or a group OCOR.sub.5 where R.sub.5 is hydrogen or R.sub.4 ; andR.sub.3 is CN;said process comprising reacting a compound of formula (II): ##STR3## wherein R.sub.1 ' is R.sub.1 or a group convertible thereto, and R.sub.3 ' is an electron withdrawing group, with a source of nitrous acid, and thereafter converting the resulting .dbd.NOH group to .dbd.NR.sub.2 wherein R.sub.2 is as defined in formula (I), converting R.sub.1 ' and R.sub.3 ' when other than R.sub.1 and R.sub.3 to R.sub.1 and R.sub.3, and thereafter optionally forming a pharmaceutically acceptable salt.
    Type: Grant
    Filed: May 12, 1995
    Date of Patent: June 30, 1998
    Assignee: SmithKline Beecham p.l.c.
    Inventors: Steven Mark Bromidge, Martyn Voyle, Erol Ali Faruk, Mark Jason Hughes, John Kitteringham, Gary Thomas Borrett
  • Derivatives of quinuclidine n-oxide as muscarinic receptor ligands
    Patent number: 5675007
    Abstract: A compound of formula (I) or a pharmaceutically acceptable salt thereof (I) wherein R.sub.1 represents (a), R.sub.2 is a group OCH.sub.3, and R.sub.3 is cyano, for use in the treatment and/or prophylaxis of dementia in mammals.
    Type: Grant
    Filed: November 12, 1996
    Date of Patent: October 7, 1997
    Assignee: SmithKline Beecham p.l.c.
    Inventors: John Keogh, Gary Thomas Borrett, Steven Mark Bromidge, Erol Ali Faruk, Mark Jason Hughes, John Kitteringham, Martyn Voyle